Down 21%, is the Smith & Nephew share price too cheap to ignore?

The Smith & Nephew share price is trading at its cheapest for almost a year. Is now the time for value investors to think about piling in, asks Royston Wild?

| More on:
Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s been a grim couple of months for Smith & Nephew (LSE:SN.) and its share price. After hitting 14-month peaks in September, the FTSE 100 business has shed a whopping 21% of its value.

Following a chilly trading update Thursday (31 October), it’s dropped back below £10 a share. And it’s still slipping in end-of-week trade.

As a long-term investor, I’m considering whether this represents a prime dip-buying opportunity. Are Smith & Nephew shares now a brilliant bargain?

Forecasts downgraded

Smith & Nephew manufactures a range of healthcare products. It’s a market leader in medical devices, along with artificial limbs and hips and products to treat wounds. And it spooked investors on Halloween by slashing its full-year forecasts.

Revenues growth in 2024’s now tipped at 4.5%, a sharp downgrade from the previously predicted 5-6%.

Trading profit margins are now forecast at “up to” 18% versus 17.5% in 2023. But this is lower than a reading of “at least” 18% previously expected. And for 2025, margins are predicted at 19-20%, down from a formerly predicted 20%.

Smith & Nephew’s suffering from weak conditions in China, and particularly at its Orthopaedics division. Group sales rose 4% in the third quarter to $1.4bn. But stripping out Chinese revenues, turnover was up 5.9% year on year.

Fragile China

China’s an enormous growth market for the company. However, destocking and rising local competition seems to be impacting Orthopaedics sales. And regarding the latter, Panmure Liberum analysts say that “it isn’t clear whether Smith & Nephew will be able to recover these revenues“.

The FTSE firm’s suffering too as the Chinese economy struggles. It had hoped the country’s centralised Volume-Based Procurement (VBP) policy would boost the number of medical procedures being performed. But the economic downturn means this hasn’t happened, hitting Sports Medicine sales as well.

Looking good long term

The issues Smith & Nephew face could take time to ease. So Thursday’s third-quarter update might not be the last trading statement to scare the market.

Having said that, I think now could be a good time to consider investing. Over the long term, demand for healthcare products is tipped to boom, driven by steady population growth and rising investment in emerging markets.

I’m certainly expecting sales to rebound sharply in China when the economic landscape improves.

It’s also encouraging to see the progress the company’s making in the US, and especially in the area of hip and knee implants.

Smith & Nephew’s diversified range of products positions it to capitalise on this structural opportunity. Its long history of innovation and creating market-leading products bodes well, as does its strong position in the fast-growing field of robotics.

For 2025, Smith & Nephew shares trade on a forward price-to-earnings (P/E) ratio of just 11.3 times. It also deals on a sub-1 price-to-earnings growth (PEG) ratio of 0.6, another figure that underlines its cheapness.

While it isn’t without risks, I think Smith & Nephew’s a great share for patient investors to consider.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 shares I’d consider for a Lifetime ISA

Our writer picks a trio of shares he believes investors should consider for a Lifetime ISA, with a mixture of…

Read more »

Investing Articles

Here are the latest share price forecasts for BAE Systems

The BAE Systems share price has risen around 130% in the last three years. Can it go higher from here?…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Growth Shares

Down 45% in 2024, is the Burberry share price worth backing for 2025?

The Burberry share price has tanked this year, losing almost half its value. Is there potential for a massive rebound…

Read more »

Investing Articles

£8,000 in savings? Here’s how I’d aim for £2,300 a month in passive income

With simply a few thousand in savings and £200 a month to invest, Muhammad Cheema looks at a strategy to…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Up 17% in a day with a 6% dividend yield? I just had to investigate this unusual penny stock

It’s not every day you see a cheap penny stock with a decent yield and enjoy a sudden growth spurt.…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

As Apple reports record Q3 sales, why’s the share price going down?

The Apple share price is falling but Stephen Wright thinks there’s plenty for shareholders to be positive about – leaving…

Read more »

Market Movers

In 1 word, here’s why the Amazon share price is rising after Q3 earnings

As revenues grow 11%, the Amazon share price is on the up. But Stephen Wright thinks that's only part of…

Read more »

Investing Articles

A UK share with a growing dividend and a yield over 10%

Roland Head looks at a UK share with a double-digit dividend yield and gives his view on whether this jumbo…

Read more »